Compare ARK Genomic Revolution ETF (ARKG) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Colgate-Palmolive Company — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Colgate-Palmolive Company trades at $92.91 (market cap $73.81B). The key difference: Colgate-Palmolive Company pays a 2.3% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Colgate-Palmolive Company nearer its low. Which is the better fit depends on your goals.
| ARKG | CL | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $99.14 |
52-Week Low | $23.09 | $74.98 |
Market Cap | — | $73.81B |
Enterprise Value | — | $80.45B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Colgate-Palmolive (CL) trades at $92.24, up 1.35% on the day, reflecting strong momentum with a bullish technical signal and consistent earnings beats. The company maintains robust profitability with a 60.06% gross margin and 10.04% net income margin, though its P/E of 35.75 and P/B of 509.03 indicate premium valuation. Recent news highlights its status as a Dividend King with a 64-year streak, supported by stable cash flow from operations of $4.20B in 2025.
Outlook remains positive with analyst consensus target of $95.56, but risks include North American segment softness and inflationary pressures. The stock offers income stability through dividends, yet high valuation multiples may limit near-term upside absent accelerated growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
